argenx SE - ESG Rating & Company Profile powered by AI
This webpage displays a free Sustainability analysis covering argenx SE. This report of argenx SE employs information from across the internet and also from available documents by argenx SE. The ESG assessment for argenx SE indicates its reporting of the United Nations Sustainable Development Goals.
argenx SE in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 4.6; made up of an environmental score of 3.0, social score of 5.0 and governance score of 5.7.
4.6
Medium ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
837 | Zentiva as | 4.7 | High |
837 | Zogenix Inc | 4.7 | High |
852 | argenx SE | 4.6 | High |
852 | Canopy Growth Corp | 4.6 | High |
852 | Novavax Inc | 4.6 | High |
... | ... | ... | |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does argenx SE have an accelerator or VC vehicle to help deliver innovation?
Does argenx SE disclose current and historical energy intensity?
Does argenx SE report the average age of the workforce?
Does argenx SE reference operational or capital allocation in relation to climate change?
Does argenx SE disclose its ethnicity pay gap?
Does argenx SE disclose cybersecurity risks?
Does argenx SE offer flexible work?
Does argenx SE have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does argenx SE disclose the number of employees in R&D functions?
Does argenx SE conduct supply chain audits?
Does argenx SE disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does argenx SE conduct 360 degree staff reviews?
Does argenx SE disclose the individual responsible for D&I?
Does argenx SE disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does argenx SE disclose current and / or historical scope 2 emissions?
Does argenx SE disclose water use targets?
Does argenx SE have careers partnerships with academic institutions?
Did argenx SE have a product recall in the last two years?
Does argenx SE disclose incidents of discrimination?
Does argenx SE allow for Work Councils/Collective Agreements to be formed?
Has argenx SE issued a profit warning in the past 24 months?
Does argenx SE disclose parental leave metrics?
Does argenx SE disclose climate scenario or pathway analysis?
Does argenx SE disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does argenx SE disclose the pay ratio of women to men?
Does argenx SE support suppliers with sustainability related research and development?
Does argenx SE disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does argenx SE reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is argenx SE involved in embryonic stem cell research?
Does argenx SE disclose GHG and Air Emissions intensity?
Does argenx SE disclose its waste policy?
Does argenx SE report according to TCFD requirements?
Does argenx SE disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does argenx SE disclose energy use targets?
Does argenx SE disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does argenx SE have a policy relating to cyber security?
Have a different question?
Potential Risks for argenx SE
These potential risks are based on the size, segment and geographies of the company.
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy in Phase III clinical trials; bullous pemphigoid and idiopathic inflammatory myopathy in Phase II/III clinical trials; and ENHANZE SC in Pre-clinical study. The company is also developing immunology innovation programs, including cusatuzumab for hematological cancer, as well as high risk MDS; ARGX-119, an antibody that targets muscle-specific tyrosine kinase stage; ARGX-117 for severe autoimmune indications; ARGX-118 for airway inflammation; and ARGX-120 to treat autoimmune diseases. In addition, its partnered product candidates include ARGX-115 for the treatment of cancer; ARGX-112 to treat interleukin-22 receptor; and ARGX-114, an antibody directed against the MET receptor. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., University of Texas, BioWa, Inc., Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.